IL154465A0 - ANTIBODIES TO HUMAN IL-1beta - Google Patents

ANTIBODIES TO HUMAN IL-1beta

Info

Publication number
IL154465A0
IL154465A0 IL15446501A IL15446501A IL154465A0 IL 154465 A0 IL154465 A0 IL 154465A0 IL 15446501 A IL15446501 A IL 15446501A IL 15446501 A IL15446501 A IL 15446501A IL 154465 A0 IL154465 A0 IL 154465A0
Authority
IL
Israel
Prior art keywords
1beta
antibodies
human
Prior art date
Application number
IL15446501A
Other languages
English (en)
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=9898090&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=IL154465(A0) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of IL154465A0 publication Critical patent/IL154465A0/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • C07K16/245—IL-1
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Diabetes (AREA)
  • Pulmonology (AREA)
  • Rheumatology (AREA)
  • Hematology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Dermatology (AREA)
  • Transplantation (AREA)
  • Ophthalmology & Optometry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Neurosurgery (AREA)
  • Toxicology (AREA)
  • Neurology (AREA)
  • Urology & Nephrology (AREA)
  • Pain & Pain Management (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
IL15446501A 2000-08-22 2001-08-20 ANTIBODIES TO HUMAN IL-1beta IL154465A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0020685.4A GB0020685D0 (en) 2000-08-22 2000-08-22 Organic compounds
PCT/EP2001/009588 WO2002016436A2 (en) 2000-08-22 2001-08-20 ANTIBODIES TO HUMAN IL-1$g(b)

Publications (1)

Publication Number Publication Date
IL154465A0 true IL154465A0 (en) 2003-09-17

Family

ID=9898090

Family Applications (2)

Application Number Title Priority Date Filing Date
IL15446501A IL154465A0 (en) 2000-08-22 2001-08-20 ANTIBODIES TO HUMAN IL-1beta
IL154465A IL154465A (en) 2000-08-22 2003-02-13 BETA1 IL-binding molecules and their use in the preparation of pharmaceuticals and drugs

Family Applications After (1)

Application Number Title Priority Date Filing Date
IL154465A IL154465A (en) 2000-08-22 2003-02-13 BETA1 IL-binding molecules and their use in the preparation of pharmaceuticals and drugs

Country Status (37)

Country Link
US (3) US7446175B2 (xx)
EP (1) EP1313769B2 (xx)
JP (2) JP4271936B2 (xx)
KR (2) KR100910789B1 (xx)
CN (1) CN100547003C (xx)
AR (1) AR035581A1 (xx)
AT (1) ATE396206T1 (xx)
AU (2) AU2001295490B2 (xx)
BE (1) BE2009C057I2 (xx)
BR (1) BR0113420A (xx)
CA (1) CA2420231C (xx)
CY (2) CY1108779T1 (xx)
CZ (1) CZ304470B6 (xx)
DE (2) DE60134148D1 (xx)
DK (1) DK1313769T4 (xx)
EC (1) ECSP034490A (xx)
ES (1) ES2305110T5 (xx)
FR (1) FR09C0062I2 (xx)
GB (1) GB0020685D0 (xx)
HK (1) HK1061403A1 (xx)
HU (2) HU228159B1 (xx)
IL (2) IL154465A0 (xx)
LU (1) LU91624I2 (xx)
MX (1) MXPA03001590A (xx)
MY (1) MY130248A (xx)
NL (1) NL300427I1 (xx)
NO (3) NO332609B1 (xx)
NZ (2) NZ534269A (xx)
PE (1) PE20020319A1 (xx)
PL (1) PL212480B1 (xx)
PT (1) PT1313769E (xx)
RU (1) RU2286351C2 (xx)
SI (1) SI1313769T2 (xx)
SK (1) SK288089B6 (xx)
TW (1) TWI321568B (xx)
WO (1) WO2002016436A2 (xx)
ZA (1) ZA200301275B (xx)

Families Citing this family (107)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1339426A4 (en) * 2000-11-08 2004-06-30 Human Genome Sciences Inc ANTIBODIES WITH IMMUNOSPECIFIC BINDING TO TRAIL RECEPTORS
NZ538569A (en) 2002-09-06 2009-02-28 Amgen Inc Therapeutic human anti-IL-1R1 monoclonal antibody
US7101978B2 (en) * 2003-01-08 2006-09-05 Applied Molecular Evolution TNF-α binding molecules
CN1780855B (zh) * 2003-01-24 2011-03-30 应用分子进化公司 人IL-1β拮抗剂
GB0303337D0 (en) 2003-02-13 2003-03-19 Celltech R&D Ltd Biological products
WO2004100987A2 (en) * 2003-05-06 2004-11-25 Regeneron Pharmaceuticals, Inc. Methods of using il-1 antagonists to treat neointimal hyperplasia
NZ549040A (en) * 2004-02-17 2009-07-31 Schering Corp Use for interleukin-33 (IL33) and the IL-33 receptor complex
EP2784090A1 (en) * 2004-02-26 2014-10-01 Baylor Research Institute Compositions for the treatment of systemic onset juvenile idiopathic arthritis
AU2012213934B9 (en) * 2005-01-26 2013-07-25 Amgen Fremont Inc. Antibodies against interleukin-1 beta
EP1851245B1 (en) * 2005-01-26 2012-10-10 Amgen Fremont Inc. Antibodies against interleukin-1 beta
GB0509512D0 (en) * 2005-05-10 2005-06-15 Novartis Ag Organic compounds
MX2007016032A (es) * 2005-06-21 2008-03-10 Xoma Technology Ltd Anticuerpos de enlace a il-1-beta y fragmentos de los mismos.
EP1940880A2 (en) * 2005-10-14 2008-07-09 Novo Nordisk A/S Treating diabetes using inhibitors of il-1
ES2944067T3 (es) * 2005-10-26 2023-06-19 Novartis Ag Uso de anticuerpos anti il-1beta
KR20110079922A (ko) 2006-04-14 2011-07-11 노파르티스 아게 안과 장애 치료를 위한 ｉｌ－1 항체의 용도
RU2554747C9 (ru) 2006-12-20 2015-10-20 Ксома (Сша) Ллс Способы лечения il-1бета-зависимых заболеваний
CL2008001071A1 (es) * 2007-04-17 2009-05-22 Smithkline Beecham Corp Metodo para obtener anticuerpo penta-especifico contra il-8/cxcl8, gro-alfa/cxcl1, gro-beta/cxcl2), gro-gama/cxcl3 y ena-78/cxcl5 humanas; anticuerpo penta-especifico; proceso de produccion del mismo; vector, hbridoma o celela que lo comprende; composicion farmceutica; uso para tratar copd, otras enfermedades.
CA3213888A1 (en) 2007-05-29 2008-12-04 Novartis Ag New indications for anti-il-i-beta therapy
EP1997832A1 (en) * 2007-05-29 2008-12-03 Ganymed Pharmaceuticals AG Monoclonal antibodies against Claudin-18 for treatment of cancer
CA2710252C (en) * 2007-12-20 2017-03-28 Xoma Technology Ltd. Methods for the treatment of gout
CA2722466A1 (en) 2008-04-29 2009-11-05 Tariq Ghayur Dual variable domain immunoglobulins and uses thereof
UY31861A (es) * 2008-06-03 2010-01-05 Abbott Lab Inmunoglobulina con dominio variable dual y usos de la misma
EP2297209A4 (en) 2008-06-03 2012-08-01 Abbott Lab IMMUNOGLOBULINS WITH TWO VARIABLE DOMAINS AND USES THEREOF
ES2398693T3 (es) * 2008-06-06 2013-03-21 Xoma Technology Ltd. Métodos para el tratamiento de la artritis reumatoide
WO2010006060A2 (en) 2008-07-08 2010-01-14 Abbott Laboratories Prostaglandin e2 dual variable domain immunoglobulins and uses thereof
US8377429B2 (en) * 2008-09-05 2013-02-19 Xoma Technology Ltd. Methods for improvement of beta cell function with anti-IL-1β antibodies or fragments thereof
JP2012506239A (ja) * 2008-10-20 2012-03-15 アボット・ラボラトリーズ Ｉｌ−１８に結合する抗体およびそれを精製する方法
US8298533B2 (en) * 2008-11-07 2012-10-30 Medimmune Limited Antibodies to IL-1R1
EP2196476A1 (en) * 2008-12-10 2010-06-16 Novartis Ag Antibody formulation
JP2012526080A (ja) * 2009-05-06 2012-10-25 ノバルティス アーゲー 抗ＩＬ１−β抗体の併用療法
US8389474B1 (en) * 2009-07-14 2013-03-05 Alan Anson Wanderer Rationale for IL-1 β targeted therapy to improve harvested organ viability, allograft tolerance, replant success and for conditions characterized by reduced or absent arterial perfusion
NZ598929A (en) * 2009-09-01 2014-05-30 Abbvie Inc Dual variable domain immunoglobulins and uses thereof
TW201119676A (en) * 2009-10-15 2011-06-16 Abbott Lab Dual variable domain immunoglobulins and uses thereof
KR102071834B1 (ko) 2009-10-26 2020-01-30 에프. 호프만-라 로슈 아게 글리코실화된 면역글로불린의 제조 방법
UY32979A (es) 2009-10-28 2011-02-28 Abbott Lab Inmunoglobulinas con dominio variable dual y usos de las mismas
BR112012028557A2 (pt) * 2010-05-07 2019-09-24 Xoma Technology Ltd. uso de um anticorpo anti-il-1b ou de fragmentos de ligação do mesmo.
JP2013537415A (ja) 2010-08-03 2013-10-03 アッヴィ・インコーポレイテッド 二重可変ドメイン免疫グロブリンおよびその使用
AU2011293253B2 (en) 2010-08-26 2014-12-11 Abbvie Inc. Dual variable domain immunoglobulins and uses thereof
EP2697260A1 (en) 2011-04-15 2014-02-19 Merck Patent GmbH Anti- il-1r1 inhibitors for use in cancer
EP2731971A1 (en) 2011-07-12 2014-05-21 Universität Zürich MODULATORS OF THE NLRP3 INFLAMMASOME IL-1ß PATHWAY FOR THE PREVENTION AND TREATMENT OF ACNE
DE102011083595A1 (de) 2011-09-28 2013-03-28 Bayer Pharma AG Inhibition der Wirkung von Interleukin 1 beta zur Behandlung der Endometriose
AR088083A1 (es) 2011-09-30 2014-05-07 Novartis Ag USO DE ANTICUERPOS DE UNION A IL-1b
WO2013082282A1 (en) 2011-12-02 2013-06-06 lNOVARTIS AG Anti-il-1beta (interleukin-1beta) antibody-based prophylactic therapy to prevent complications leading to vaso-occlusion in sickle cell disease.
CN107459576A (zh) 2011-12-14 2017-12-12 艾伯维德国有限责任两合公司 用于诊断和治疗铁相关病症的组合物和方法
WO2013087914A1 (en) 2011-12-16 2013-06-20 Synthon Biopharmaceuticals B.V. EXPRESSION OF SECRETORY IgA ANTIBODIES IN DUCKWEED
EP3050900A1 (en) 2011-12-19 2016-08-03 Xoma (Us) Llc Methods for treating acne
CA2861610A1 (en) 2011-12-30 2013-07-04 Abbvie Inc. Dual specific binding proteins directed against il-13 and/or il-17
SG10201708562VA (en) * 2012-02-13 2017-12-28 Agency Science Tech & Res IL-1β Neutralizing Human Monoclonal Antibodies
CN103588878A (zh) * 2012-08-15 2014-02-19 江苏泰康生物医药有限公司 一种人源化抗人白细胞介素1 β单克隆抗体及其制备与应用
NZ707641A (en) 2012-11-01 2016-09-30 Abbvie Inc Anti-vegf/dll4 dual variable domain immunoglobulins and uses thereof
BR112015009892B1 (pt) * 2012-11-05 2022-12-27 Delenex Therapeutics Ag Anticorpo contra il-1 beta, seu método de produção e seu uso, sequência isolada de ácido nucleico, vetor, composição cosmética, de diagnóstico ou farmacêutica, e kit
WO2014078502A1 (en) 2012-11-16 2014-05-22 Novartis Ag Use of il-1 beta binding antibodies for treating peripheral arterial disease
EP2931750B8 (en) 2012-12-17 2021-11-03 Cell Medica Inc. Antibodies against il-1 beta
CA2891686A1 (en) 2012-12-18 2014-06-26 Novartis Ag Compositions and methods that utilize a peptide tag that binds to hyaluronan
TW201512219A (zh) 2013-03-15 2015-04-01 Abbvie Inc 針對ＩＬ－１β及／或ＩＬ－１７之雙特異性結合蛋白
WO2015083120A1 (en) 2013-12-04 2015-06-11 Novartis Ag USE OF IL-1β BINDING ANTIBODIES
WO2015198240A2 (en) 2014-06-25 2015-12-30 Novartis Ag Compositions and methods for long acting proteins
WO2015198243A2 (en) 2014-06-25 2015-12-30 Novartis Ag Compositions and methods for long acting proteins
WO2016008851A1 (en) * 2014-07-14 2016-01-21 Boehringer Ingelheim International Gmbh Anti-il-1b antibodies
MA41044A (fr) 2014-10-08 2017-08-15 Novartis Ag Compositions et procédés d'utilisation pour une réponse immunitaire accrue et traitement contre le cancer
CR20170143A (es) 2014-10-14 2017-06-19 Dana Farber Cancer Inst Inc Moléculas de anticuerpo que se unen a pd-l1 y usos de las mismas
KR20170082594A (ko) 2014-11-10 2017-07-14 에프. 호프만-라 로슈 아게 항-ang2 항체 및 사용 방법
KR20170080584A (ko) 2014-11-10 2017-07-10 에프. 호프만-라 로슈 아게 이중특이적 항체 및 안과학에서 이의 사용 방법
WO2016094881A2 (en) 2014-12-11 2016-06-16 Abbvie Inc. Lrp-8 binding proteins
AU2016272900A1 (en) 2015-06-04 2017-12-07 Novartis Ag Use of IL-1 beta binding antibodies to treat peripheral arterial disease
TW201710286A (zh) 2015-06-15 2017-03-16 艾伯維有限公司 抗ｖｅｇｆ、ｐｄｇｆ及／或其受體之結合蛋白
US20180207273A1 (en) 2015-07-29 2018-07-26 Novartis Ag Combination therapies comprising antibody molecules to tim-3
PT3317301T (pt) 2015-07-29 2021-07-09 Novartis Ag Terapias de associação compreendendo moléculas de anticorpo contra lag-3
WO2017019896A1 (en) 2015-07-29 2017-02-02 Novartis Ag Combination therapies comprising antibody molecules to pd-1
AU2016369537B2 (en) 2015-12-17 2024-03-14 Novartis Ag Antibody molecules to PD-1 and uses thereof
EP3426775A1 (en) 2016-03-10 2019-01-16 Novartis AG Chemically modified messenger rna's
AU2017298656A1 (en) 2016-07-21 2019-02-07 Novartis Ag Use of the IL-1beta binding antibody canakinumab for treating or allevating symptoms of pulmonary sarcoidosis
EP4252629A3 (en) 2016-12-07 2023-12-27 Biora Therapeutics, Inc. Gastrointestinal tract detection methods, devices and systems
US20200315540A1 (en) 2016-12-14 2020-10-08 Progenity, Inc. Treatment of a disease of the gastrointestinal tract with an il-1 inhibitor
UY37758A (es) 2017-06-12 2019-01-31 Novartis Ag Método de fabricación de anticuerpos biespecíficos, anticuerpos biespecíficos y uso terapéutico de dichos anticuerpos
US20190048072A1 (en) 2017-06-22 2019-02-14 Novartis Ag USE OF IL-1beta BINDING ANTIBODIES
WO2018235056A1 (en) 2017-06-22 2018-12-27 Novartis Ag IL-1BETA BINDING ANTIBODIES FOR USE IN THE TREATMENT OF CANCER
US20200158716A1 (en) * 2017-07-17 2020-05-21 Massachusetts Institute Of Technology Cell atlas of healthy and diseased barrier tissues
EP3710475A1 (en) 2017-08-25 2020-09-23 Novartis AG Use of canakinumab
JP2020533353A (ja) 2017-09-13 2020-11-19 ノバルティス アーゲー アルコール性肝炎の治療のためのｉｌ−１ｂ結合抗体の使用
CN111655288A (zh) 2017-11-16 2020-09-11 诺华股份有限公司 组合疗法
CN112584857A (zh) * 2018-05-09 2021-03-30 诺华股份有限公司 卡那吉努单抗的用途
US11492409B2 (en) 2018-06-01 2022-11-08 Novartis Ag Binding molecules against BCMA and uses thereof
AR116109A1 (es) 2018-07-10 2021-03-31 Novartis Ag Derivados de 3-(5-amino-1-oxoisoindolin-2-il)piperidina-2,6-diona y usos de los mismos
GB2575853A (en) * 2018-07-25 2020-01-29 Robert Wotherspoon Hugh IL-1ß binding antibody
CN110818793A (zh) * 2018-08-14 2020-02-21 中山康方生物医药有限公司 抗IL-1β的抗体、其药物组合物及其用途
WO2020039401A1 (en) 2018-08-24 2020-02-27 Novartis Ag Treatment comprising il-1βeta binding antibodies and combinations thereof
US11976115B2 (en) * 2018-11-07 2024-05-07 Zeda Biopharmaceuticals, Inc. Antibody binding to human IL-1β, preparation method therefor and use thereof
KR20210095165A (ko) 2018-11-19 2021-07-30 프로제너티, 인크. 바이오의약품으로 질환을 치료하기 위한 방법 및 디바이스
KR20210106437A (ko) 2018-12-20 2021-08-30 노파르티스 아게 3-(1-옥소이소인돌린-2-일)피페리딘-2,6-디온 유도체를 포함하는 투약 요법 및 약학적 조합물
WO2020128613A1 (en) 2018-12-21 2020-06-25 Novartis Ag Use of il-1beta binding antibodies
GB201901187D0 (en) 2019-01-29 2019-03-20 Autolus Ltd Treatment of neurotoxicity and/or cytokine release syndrome
CN113490528A (zh) 2019-02-15 2021-10-08 诺华股份有限公司 3-(1-氧代-5-(哌啶-4-基)异吲哚啉-2-基)哌啶-2,6-二酮衍生物及其用途
EP3924055B1 (en) 2019-02-15 2024-04-03 Novartis AG Substituted 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof
WO2021116789A1 (en) 2019-12-09 2021-06-17 Novartis Ag Anti-interleukin 1 beta antibodies for treatment of sickle cell disease
CN115666704A (zh) 2019-12-13 2023-01-31 比奥拉治疗股份有限公司 用于将治疗剂递送至胃肠道的可摄取装置
MX2022007759A (es) 2019-12-20 2022-07-19 Novartis Ag Combinacion del anticuerpo anti tim-3 mbg453 y anticuerpo anti tgf-beta nis793, con o sin decitabina o el anticuerpo anti pd-1 spartalizumab, para el tratamiento de mielofibrosis y sindrome mielodisplasico.
TWI793503B (zh) * 2020-01-20 2023-02-21 美商美國禮來大藥廠 抗IL-1β抗體
WO2021257539A1 (en) * 2020-06-16 2021-12-23 Academia Sinica ANTIBODIES TO INTERLEUKIN-1β AND USES THEREOF
CN115916199A (zh) 2020-06-23 2023-04-04 诺华股份有限公司 包含3-(1-氧代异吲哚啉-2-基)哌啶-2,6-二酮衍生物的给药方案
WO2022023907A1 (en) 2020-07-31 2022-02-03 Novartis Ag Methods of selecting and treating patients at elevated risk of major adverse cardiac events
WO2022097060A1 (en) 2020-11-06 2022-05-12 Novartis Ag Cd19 binding molecules and uses thereof
WO2022167916A1 (en) 2021-02-03 2022-08-11 Novartis Ag Use of il-1b binding antibodies for treating neuroinflammatory disorders
TW202304979A (zh) 2021-04-07 2023-02-01 瑞士商諾華公司 抗ＴＧＦβ抗體及其他治療劑用於治療增殖性疾病之用途
AR125874A1 (es) 2021-05-18 2023-08-23 Novartis Ag Terapias de combinación
JP2024519893A (ja) 2021-05-24 2024-05-21 ノバルティス アーゲー 変形性関節症の治療方法
US20240294626A1 (en) 2021-06-22 2024-09-05 Novartis Ag Bispecific antibodies for use in treatment of hidradenitis suppurativa

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US534858A (en) * 1895-02-26 Workman s time-recorder
CA1172789A (en) 1980-09-25 1984-08-14 Hideo Kasahara POLYMERIC MATERIAL COMPRISING A POLYAMIDE BONDED TO A COPOLYMER CONTAINING AN IMIDE OF AN .alpha.,.beta. UNSATURATED CARBOXYLIC ACID
US4772685A (en) 1985-10-02 1988-09-20 Merck & Co., Inc. Immunogenic peptides of human interleukin-1 and the corresponding anti-peptide antibodies
GB8601597D0 (en) 1986-01-23 1986-02-26 Wilson R H Nucleotide sequences
US4935343A (en) 1986-08-08 1990-06-19 Syntex (U.S.A.) Inc. Monoclonal antibodies for interleukin-1β
DE3785186T2 (de) 1986-09-02 1993-07-15 Enzon Lab Inc Bindungsmolekuele mit einzelpolypeptidkette.
DK590387A (da) * 1986-11-13 1988-05-14 Otsuka Pharma Co Ltd Antistoffer mod interleukin-1
GB8717430D0 (en) 1987-07-23 1987-08-26 Celltech Ltd Recombinant dna product
GB8809129D0 (en) 1988-04-18 1988-05-18 Celltech Ltd Recombinant dna methods vectors and host cells
EP0364778B1 (en) 1988-10-01 1996-03-13 Otsuka Pharmaceutical Co., Ltd. Antibody against interleukin-1beta
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
FR2640146B1 (fr) 1988-12-08 1993-12-24 Commissariat A Energie Atomique Anticorps monoclonaux anti-interleukines 1(alpha) et 1(beta), leur procede de production et applications desdits anticorps a la detection des interleukines 1(alpha) et 1(beta) et en therapeutique
IL162181A (en) 1988-12-28 2006-04-10 Pdl Biopharma Inc A method of producing humanized immunoglubulin, and polynucleotides encoding the same
CA2018248A1 (en) 1989-06-07 1990-12-07 Clyde W. Shearman Monoclonal antibodies against the human alpha/beta t-cell receptor, their production and use
US5859205A (en) 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
GB8928874D0 (en) 1989-12-21 1990-02-28 Celltech Ltd Humanised antibodies
JP3068180B2 (ja) 1990-01-12 2000-07-24 アブジェニックス インコーポレイテッド 異種抗体の生成
GB9014932D0 (en) 1990-07-05 1990-08-22 Celltech Ltd Recombinant dna product and method
ATE158021T1 (de) 1990-08-29 1997-09-15 Genpharm Int Produktion und nützung nicht-menschliche transgentiere zur produktion heterologe antikörper
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5770429A (en) 1990-08-29 1998-06-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
JP3714683B2 (ja) 1992-07-30 2005-11-09 生化学工業株式会社 抗リウマチ剤
US5429614A (en) 1993-06-30 1995-07-04 Baxter International Inc. Drug delivery system
WO1995001997A1 (en) * 1993-07-09 1995-01-19 Smithkline Beecham Corporation RECOMBINANT AND HUMANIZED IL-1β ANTIBODIES FOR TREATMENT OF IL-1 MEDIATED INFLAMMATORY DISORDERS IN MAN
US6309636B1 (en) * 1995-09-14 2001-10-30 Cancer Research Institute Of Contra Costa Recombinant peptides derived from the Mc3 anti-BA46 antibody, methods of use thereof, and methods of humanizing antibody peptides
US6051228A (en) 1998-02-19 2000-04-18 Bristol-Myers Squibb Co. Antibodies against human CD40
GB0001448D0 (en) 2000-01-21 2000-03-08 Novartis Ag Organic compounds

Also Published As

Publication number Publication date
LU91624I2 (fr) 2010-01-25
PL212480B1 (pl) 2012-10-31
NO2012018I2 (no) 2012-11-21
US20090081732A1 (en) 2009-03-26
HUS1300015I1 (hu) 2021-05-28
CY2009019I1 (el) 2012-01-25
US20110256151A1 (en) 2011-10-20
JP2004506448A (ja) 2004-03-04
KR100910789B1 (ko) 2009-08-04
NO20030827D0 (no) 2003-02-21
CZ2003505A3 (cs) 2003-05-14
CA2420231C (en) 2011-04-26
WO2002016436A2 (en) 2002-02-28
PE20020319A1 (es) 2002-06-11
WO2002016436A3 (en) 2002-06-20
IL154465A (en) 2010-11-30
BRPI0113420B1 (pt) 2002-02-28
EP1313769B2 (en) 2011-11-09
RU2286351C2 (ru) 2006-10-27
CZ304470B6 (cs) 2014-05-21
SK2132003A3 (en) 2003-10-07
CY2009019I2 (el) 2017-07-12
KR20080056316A (ko) 2008-06-20
NZ534269A (en) 2006-04-28
BRPI0113420B8 (xx) 2021-05-25
LU91624I9 (xx) 2018-11-19
TWI321568B (en) 2010-03-11
DK1313769T4 (da) 2011-12-05
AU9549001A (en) 2002-03-04
EP1313769A2 (en) 2003-05-28
PL360358A1 (en) 2004-09-06
SK288089B6 (sk) 2013-06-03
ATE396206T1 (de) 2008-06-15
MXPA03001590A (es) 2003-06-04
KR20030034140A (ko) 2003-05-01
SI1313769T2 (sl) 2012-01-31
AR035581A1 (es) 2004-06-16
HUP0300806A3 (en) 2005-09-28
ZA200301275B (en) 2004-04-02
FR09C0062I1 (xx) 2010-08-01
FR09C0062I2 (fr) 2010-12-31
SI1313769T1 (sl) 2008-10-31
CN100547003C (zh) 2009-10-07
JP4271936B2 (ja) 2009-06-03
NZ524199A (en) 2004-09-24
JP2008295456A (ja) 2008-12-11
MY130248A (en) 2007-06-29
NL300427I2 (en) 2010-02-01
HU228159B1 (en) 2013-01-28
PT1313769E (pt) 2008-08-26
NO2017052I2 (no) 2018-05-14
ES2305110T3 (es) 2008-11-01
US20040063913A1 (en) 2004-04-01
NO2012018I1 (no) 2012-12-10
US7446175B2 (en) 2008-11-04
NO2017052I1 (no) 2017-10-11
US8273350B2 (en) 2012-09-25
NO20030827L (no) 2003-04-14
DK1313769T3 (da) 2008-09-15
CY1108779T1 (el) 2012-01-25
DE60134148D1 (de) 2008-07-03
GB0020685D0 (en) 2000-10-11
NO332609B1 (no) 2012-11-19
DE122009000078I1 (de) 2010-03-25
BR0113420A (pt) 2003-07-29
CA2420231A1 (en) 2002-02-28
ES2305110T5 (es) 2012-03-13
HUP0300806A2 (hu) 2003-12-29
CN1484652A (zh) 2004-03-24
NL300427I1 (en) 2010-02-01
HK1061403A1 (en) 2004-09-17
AU2001295490B2 (en) 2005-06-16
EP1313769B1 (en) 2008-05-21
ECSP034490A (es) 2003-03-31
BE2009C057I2 (xx) 2021-01-28
US7993878B2 (en) 2011-08-09

Similar Documents

Publication Publication Date Title
HUS1300015I1 (hu) Humán IL-1béta elleni antitestek
AU4835001A (en) Antibodies to human cd154
HK1050013A1 (zh) 抗人IL-1β抗體
AU8390301A (en) Antibodies to human MCP-1
GB0028926D0 (en) Improvements relating to skin prickers
GB0103973D0 (en) Improvements relating to skin prickers
AU6269101A (en) Cosmetic preparation
IL160998A0 (en) Human tissue factor antibodies
GB0103977D0 (en) Improvements relating to skin prickers
AU7522401A (en) Non-agonistic antibodies to human gp39, compositions containing, and therapeuticuse thereof
AU4319001A (en) Microcompetiton and human disease
GB0004795D0 (en) Improvements relating to patient carrying platforms
AR028262A1 (es) Anticuerpos especificos de fap-alfa humanos
GB0005218D0 (en) Improvements relating to patient carrying structures
GB0226332D0 (en) Skin preparation
AU9481201A (en) Human nedd-1
GB0024673D0 (en) Therapeutic antibodies
SE0000819D0 (sv) Skin preparation
CA89697S (en) Walker
CA89698S (en) Walker
GB0017139D0 (en) Human monoclonal antibodies
GB0016824D0 (en) Human monoclonal antibodies
GB0023336D0 (en) Skin care compositions
GB0012565D0 (en) Skin care compositions
GB0012564D0 (en) Skin care compositions

Legal Events

Date Code Title Description
EXTE Period for filing application for extension order has been extended (section 64p.(4))